Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels-Reference-Cited by-同舟云学术

Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels

Published:2012-11-27 Issue:9 Volume:48 Page:1051-1060
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Yoneda Masato, ,Imajo Kento,Eguchi Yuichiro,Fujii Hideki,Sumida Yoshio,Hyogo Hideyuki,Ono Masafumi,Suzuki Yasuaki,Kawaguchi Takumi,Aoki Noriaki,Sata Michio,Kanemasa Kazuyuki,Kohgo Yutaka,Saibara Toshiji,Chayama Kazuaki,Itoh Yoshito,Yoshikawa Toshikazu,Anzai Keizo,Fujimoto Kazuma,Okanoue Takeshi,Nakajima Atsushi

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-012-0704-y.pdf

Reference42 articles.

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;18:1221–31.

2. Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl 1):S11–6.

3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.

4. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106–10.

5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–19.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of liver fibrosis by transient elastography and procollagen III amino terminal propeptide in rheumatoid arthritis patients treated with methotrexate;Egyptian Journal of Radiology and Nuclear Medicine;2024-08-05

2. Assessment of Liver Involvement in Patients With Type 2 Diabetes Mellitus in Basrah City, Iraq, Using FibroScan and Correlation With Risk Factors;Cureus;2024-07-22

3. Dual blockade of interleukin-17A and interleukin-17F as a therapeutic strategy for liver fibrosis: Investigating the potential effect and mechanism of brodalumab;Cytokine;2024-06

4. Importance of ALT levels of >30 in patients with MASLD: Nara Declaration 2023;Kanzo;2024-04-01

5. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis;Hepatology;2024-03-15